FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Anne de Papp

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Anatomy

Physiology

Co-author Network

Publications

TOP 3
Kim Brixen; Roland Chapurlat; Angela M Cheung; Bernard Dardzinski; Klaus Engelke; Thomas Fuerst; Tony M Keaveny; Robert Recker; Elizabeth Rosenberg; Nadia Verbruggen; Shabana Ather; Anne E de Papp
Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
Brendan F Boyce; Anne E de Papp; Elizabeth Rosenberg; Le T Duong
The osteoclast, bone remodelling and treatment of metabolic bone disease.
Jenny Folkesson; Janet Goldenstein; Julio Carballido-Gamio; Galateia Kazakia; Andrew Burghardt; Ana Rodriguez; Roland Krug; Anne E de Papp; Thomas M Link; Sharmila Majumdar
Longitudinal evaluation of the effects of alendronate on MRI bone microarchitecture in postmenopausal osteopenic women.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Anne de Papp (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Kim Brixen; Roland Chapurlat; Angela M Cheung; Bernard Dardzinski; Klaus Engelke; Thomas Fuerst; Tony M Keaveny; Robert Recker; Elizabeth Rosenberg; Nadia Verbruggen; Shabana Ather; Anne E de Papp
Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
The Journal of clinical endocrinology and metabolism 2013;98(2):571-80.
2012: Brendan F Boyce; Anne E de Papp; Elizabeth Rosenberg; Le T Duong
The osteoclast, bone remodelling and treatment of metabolic bone disease.
European journal of clinical investigation 2012;42(12):1332-41.
2011: Jenny Folkesson; Janet Goldenstein; Julio Carballido-Gamio; Galateia Kazakia; Andrew Burghardt; Ana Rodriguez; Roland Krug; Anne E de Papp; Thomas M Link; Sharmila Majumdar
Longitudinal evaluation of the effects of alendronate on MRI bone microarchitecture in postmenopausal osteopenic women.
Bone 2011;48(3):611-21.
2010: Andrew Burghardt; Galateia J Kazakia; Miki Sode; Anne E de Papp; Thomas M Link; Sharmila Majumdar
A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2010;25(12):2558-71.
2010: Dale W Stovall; Mary K Beard; Suzanne Barbier; Erluo Chen; Elizabeth Rosenberg; Anne E de Papp
Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
Journal of women's health (2002) 2010;19(3):491-7.
2009: Sydney Lou Bonnick; Thomas J Beck; F Cosman; Marc C Hochberg; H Wang; Anne E de Papp
DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2009;20(6):911-21.
2009: Sherri-Ann M Burnett-Bowie; Kenneth G Saag; Anthony Sebba; Anne E de Papp; Erluo Chen; Elizabeth Rosenberg; Susan L Greenspan
Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates.
The Journal of clinical endocrinology and metabolism 2009;94(4):1097-103.
2008: Galateia Kazakia; Benedict Hyun; Andrew Burghardt; Roland Krug; David Newitt; Anne E de Papp; Thomas M Link; Sharmila Majumdar
In vivo determination of bone structure in postmenopausal women: a comparison of HR-pQCT and high-field MR imaging.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2008;23(4):463-74.
2007: Anne E de Papp; Henry G Bone; Michael P Caulfield; Risa Kagan; Anna Buinewicz; Erluo Chen; Elizabeth Rosenberg; Richard E Reitz
A cross-sectional study of bone turnover markers in healthy premenopausal women.
Bone 2007;40(5):1222-30.
2006: Sydney Lou Bonnick; Kenneth G Saag; Douglas P Kiel; Michael R McClung; Marc C Hochberg; Sherri-Ann M Burnett; Anthony I Sebba; Risa Kagan; Erluo Chen; Desmond E Thompson; Anne E de Papp
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.
The Journal of clinical endocrinology and metabolism 2006;91(7):2631-7.
2005: Byron Cryer; Neil Binkley; Christine Simonelli; E Michael Lewiecki; Frank Lanza; Erluo Chen; Richard A Petruschke; Christine Mullen; Anne E de Papp
A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis.
The American journal of geriatric pharmacotherapy 2005;3(3):127-36.
2005: Michael F Holick; Ethel S Siris; Neil Binkley; Mary K Beard; Aliya Khan; Jennifer T Katzer; Richard A Petruschke; Erluo Chen; Anne E de Papp
Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy.
The Journal of clinical endocrinology and metabolism 2005;90(6):3215-24.
2005: Clifford J Rosen; Marc C Hochberg; Sydney Lou Bonnick; Michael R McClung; Paul Miller; Susan Broy; Risa Kagan; Erluo Chen; Richard A Petruschke; Desmond E Thompson; Anne E de Papp
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2005;20(1):141-51.
2004: Anthony I Sebba; Sydney Lou Bonnick; Risa Kagan; Desmond E Thompson; Carol S Skalky; Erluo Chen; Anne E de Papp
Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.
Current medical research and opinion 2004;20(12):2031-41.
2004: Marjorie Luckey; Risa Kagan; Susan L Greenspan; Henry G Bone; R Douglas P Kiel; James Simon; Jennifer Sackarowitz; Joanne Palmisano; Erluo Chen; Richard A Petruschke; Anne E de Papp
Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis.
Menopause (New York, N.Y.) 2004;11(4):405-15.
2002: Susan L Greenspan; Ellen Field-Munves; Richard P Tonino; Mary Smith; Richard A Petruschke; Lixia Wang; John Yates; Anne E de Papp; Joanne Palmisano
Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study.
Mayo Clinic proceedings. Mayo Clinic 2002;77(10):1044-52.
2002: Reetu Singh; Marluce Bibbo; Mary F Cunnane; John A Carlson; Anne E de Papp
Metastatic cervical carcinoma with ectopic calcitonin production presenting as a thyroid mass.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2002;8(1):50-3.
1997: P S Najm; E B Ruby; Anne E de Papp
A 37-year-old female with a shoulder mass and hypertensive crisis.
The Journal of clinical endocrinology and metabolism 1997;82(12):3972-5.